Bionano Genomics (NASDAQ:BNGO) Trading Down 4.2%

Bionano Genomics, Inc. (NASDAQ:BNGO) dropped 4.2% during mid-day trading on Wednesday . The stock traded as low as $0.76 and last traded at $0.76. Approximately 795,720 shares were traded during trading, a decline of 52% from the average daily volume of 1,645,953 shares. The stock had previously closed at $0.79.

Analyst Upgrades and Downgrades

Separately, Scotiabank decreased their price objective on shares of Bionano Genomics from $7.00 to $6.00 and set a “sector outperform” rating for the company in a report on Thursday, March 7th.

Bionano Genomics Trading Down 4.2 %

The company has a current ratio of 1.40, a quick ratio of 1.17 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average is $1.07 and its 200-day moving average is $1.38. The firm has a market capitalization of $41.62 million, a P/E ratio of -0.11 and a beta of 2.33.

Bionano Genomics (NASDAQ:BNGO) last posted its quarterly earnings data on Tuesday, March 5th. The company reported ($0.96) earnings per share (EPS) for the quarter. Bionano Genomics had a negative return on equity of 103.68% and a negative net margin of 643.74%. The firm had revenue of $10.72 million for the quarter. As a group, sell-side analysts anticipate that Bionano Genomics, Inc. will post -2.35 earnings per share for the current fiscal year.

Institutional Trading of Bionano Genomics

Hedge funds have recently bought and sold shares of the stock. Dark Forest Capital Management LP boosted its holdings in Bionano Genomics by 1,024.2% in the 3rd quarter. Dark Forest Capital Management LP now owns 141,747 shares of the company’s stock valued at $429,000 after purchasing an additional 129,138 shares during the period. Quadrature Capital Ltd bought a new stake in Bionano Genomics in the 4th quarter valued at $209,000. Cantor Fitzgerald L. P. boosted its holdings in Bionano Genomics by 22.2% in the 4th quarter. Cantor Fitzgerald L. P. now owns 55,000 shares of the company’s stock valued at $104,000 after purchasing an additional 10,000 shares during the period. Headlands Technologies LLC bought a new stake in Bionano Genomics in the 4th quarter valued at $72,000. Finally, Carret Asset Management LLC bought a new stake in Bionano Genomics in the 4th quarter valued at $34,000. 11.35% of the stock is owned by institutional investors.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.